Table 1.

Surface marker expression of MSCs and pre-osteoblast untreated or treated with OS-EVs (-EVs/+EVs), n = 3 repeated 3 times. As controls, MSCs treated with autologous EVs, as well as cell lines (HOS143b, U2O and BM-MSCs) were used. CD, cluster of differentiation.

	OS-EV treatment group				Controls
	MSC -EVs	MSC +EVs	Pre-osteo -EVs	Pre-osteo +EVs	MSC +autoMSC EVs (n = 3)	HOS143b (n = 2)	U2OS (n = 1)	BM-MSC (n = 3)
CD14						0.3 ± 0.1	0.2	0.3. ± 0.1
CD19						0.2 ± 0.1	0.1	0.1. ± 0.1
CD34						2.2 ± 2.8	0.2	1.1. ± 1.7
CD45						0.4 ± 0.2	0.3	0.3 ± 0.1
CD54	27.6 ± 19.1	46.7 ± 38.4	50.0 ± 8.8	79.4 ± 6.1	7.2 ± 0.45	99.7 ± 0.7	5.9	12.6 ± 2.3
CD73	98.1 ± 2.6	98.8 ± 1.9	99.5 ± 0.2	99.7 ± 0.1	98.0 ± 0.7	99 ± 1.2	0.4	99.4 ± 0.4
CD90						4 ± 4.1	99	97.6 ± 0.0
CD105						97.7 ± 0.9	37.1	96.6 ± 1.2
HLA-DR						0.9 ± 0.3	0.5	1.3 ± 0.4
CD106	0.1 ± 0.1	0.6 ± 0.7	0.3 ± 0.2	0.3 ± 0.2	0.1 ± 0.7	0	0.2	41.4
CD271	0.0 ± 0.1	0.1 ± 0.1	0.2 ± 0.1	0.1 ± 0.1	0.1 ± 0.1	1.9	86.9	24.5